1. Home
  2. KTB vs IOVA Comparison

KTB vs IOVA Comparison

Compare KTB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kontoor Brands Inc.

KTB

Kontoor Brands Inc.

HOLD

Current Price

$66.55

Market Cap

3.8B

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTB
IOVA
Founded
2018
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
968.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KTB
IOVA
Price
$66.55
$2.15
Analyst Decision
Strong Buy
Buy
Analyst Count
8
12
Target Price
$96.38
$10.36
AVG Volume (30 Days)
643.7K
9.8M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
3.19%
N/A
EPS Growth
N/A
N/A
EPS
3.88
N/A
Revenue
$2,833,659,000.00
$250,425,000.00
Revenue This Year
$20.46
$60.94
Revenue Next Year
$11.11
$60.85
P/E Ratio
$17.15
N/A
Revenue Growth
9.91
175.62
52 Week Low
$50.00
$1.64
52 Week High
$96.80
$8.56

Technical Indicators

Market Signals
Indicator
KTB
IOVA
Relative Strength Index (RSI) 34.26 44.43
Support Level $65.89 $2.18
Resistance Level $69.73 $2.32
Average True Range (ATR) 2.77 0.11
MACD -0.66 -0.02
Stochastic Oscillator 0.00 7.36

Price Performance

Historical Comparison
KTB
IOVA

About KTB Kontoor Brands Inc.

Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: